{"filing":{"accession_number":"0001193125-26-349136","cik":"0001510964","ticker":"CVSI","company_name":"CV Sciences, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-05-14","primary_document":"cvsi-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/cvsi-20260813.htm"},"events":[{"id":27580,"run_id":25148,"accession_number":"0001193125-26-349136","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"CV Sciences disclosed its second quarter 2026 financial results on August 13, 2026, reporting revenue of $3.0 million (down 17.5% year-over-year), gross margin of 48.6%, operating loss of $0.3 million, and net loss of $0.775 million, along with consolidated financial statements and non-GAAP reconciliations.","company_name":"CV Sciences, Inc.","ticker":"CVSI","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29166,"accession_number":"0001193125-26-349136","item_number":"2.02","item_title":"Results of Operations and Financial Conditions","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CV Sciences disclosed its second quarter 2026 financial results via press release dated August 13, 2026, reporting Q2 2026 revenue of $3.0 million (down 17.5% YoY), operating loss of $0.3 million, and net loss of $0.775 million. The filing includes consolidated statements of operations, balance sheets, and cash flows for the periods ended June 30, 2026, along with non-GAAP reconciliations. This is a standard quarterly earnings release material to investors assessing the company's financial performance and operational trends.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:13.437372+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29167,"accession_number":"0001193125-26-349136","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CV Sciences issued a press release on August 13, 2026 disclosing its financial results for the quarter ended June 30, 2026, including revenue of $3.0 million, gross margin of 48.6%, operating loss of $0.3 million, and adjusted EBITDA loss of $0.1 million. The filing explicitly states this is furnished under Item 7.01 (Regulation FD Disclosure) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes consolidated statements of operations, balance sheets, cash flows, and non-GAAP reconciliations, all characteristic of a quarterly earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:13.437372+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29166,"accession_number":"0001193125-26-349136","item_number":"2.02","item_title":"Results of Operations and Financial Conditions","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CV Sciences disclosed its second quarter 2026 financial results via press release dated August 13, 2026, reporting Q2 2026 revenue of $3.0 million (down 17.5% YoY), operating loss of $0.3 million, and net loss of $0.775 million. The filing includes consolidated statements of operations, balance sheets, and cash flows for the periods ended June 30, 2026, along with non-GAAP reconciliations. This is a standard quarterly earnings release material to investors assessing the company's financial performance and operational trends.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:13.437372+00:00","company_name":"CV Sciences, Inc.","ticker":"CVSI","filing_date":"2026-08-13"},{"id":29167,"accession_number":"0001193125-26-349136","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CV Sciences issued a press release on August 13, 2026 disclosing its financial results for the quarter ended June 30, 2026, including revenue of $3.0 million, gross margin of 48.6%, operating loss of $0.3 million, and adjusted EBITDA loss of $0.1 million. The filing explicitly states this is furnished under Item 7.01 (Regulation FD Disclosure) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes consolidated statements of operations, balance sheets, cash flows, and non-GAAP reconciliations, all characteristic of a quarterly earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:13.437372+00:00","company_name":"CV Sciences, Inc.","ticker":"CVSI","filing_date":"2026-08-13"}]}